Salix Pharmaceuticals, Ltd. Release: Fulyzaq® (Crofelemer) 125 Mg Delayed-Release Tablets Significantly Improves Noninfectious Diarrhea In Adult Patients Living With HIV On ART Therapy
RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that HIV Clinical Trials, an international, peer-reviewed journal focused on human immunodeficiency virus (HIV)/ acquired immune deficiency syndrome (AIDS) research, published a study that supports the efficacy and safety of Fulyzaq® (crofelemer) for the treatment of noninfectious diarrhea caused by anti-retroviral therapy (ART) in adult patients with HIV. The Antidiarrhea Therapy in HIV Disease-Emerging Treatment Concepts (ADVENT) trial concluded that Fulyzaq provides significant improvement in the symptomatic relief of noninfectious diarrhea with a safety profile similar to placebo and with no negative impact on clinical immune parameters (HIV viral load and CD4+ cell count). The study appears in the November /December issue of HIV Clinical Trials.
Help employers find you! Check out all the jobs and post your resume.